Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IBRXBullishIndustry Newsnews

High materiality7/10

ImmunityBio's ANKTIVA data bolster long-term UMIBC prospects for IBRX

Oct 19, 2026, 12:12 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong efficacy signals (71% CR, long-term durability) and survival metrics support a fundamental uplift. Regulatory expansions (FDA history and UAE approval) could broaden addressable market; near-term volatility may temper gains until tests around $11 and above are cleared.

AI summary

What happened, with direct paths to the underlying reporting

New long-term data from QUILT-3.032 show ANKTIVA plus BCG delivering durable remissions in BCG-unresponsive NMIBC with strong survival signals and a favorable safety profile. The results strengthen ImmunityBio's clinical case and may support further regulatory expansion, including UAE approvals, potentially expanding addressable market and sustaining upside for IBRX into upcoming catalysts.

QUILT-3.032: ANKTIVA+BCG achieved 71% complete response.
Median duration 26.6 months; responses extend beyond 53 months.
84% cystectomy-free survival at 36 months; 98.2% disease-specific survival at 3 years.
No Grade 4 or 5 treatment-related adverse events; most events mild.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

ImmunityBio's ANKTIVA data bolster long-term UMIBC prospects for IBRX

FDA expands ANKTIVA label for NMIBC, signaling potential near-term IBRX upside

ImmunityBio's IBRX breaks above $10.50, signaling possible continuation

Emirates approves ANKTIVA, expanding IBRX footprint and potential catalysts

ImmunityBio's ANKTIVA Shows Promising Results, But Shares Decline